Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia

Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):20-6. doi: 10.1161/01.atv.18.1.20.

Abstract

Hypertriglyceridemia and impaired fibrinolytic function are linked to coronary heart disease and other atherothrombotic disorders. Triglyceride-rich lipoproteins may attenuate fibrinolysis by increasing the plasma levels of plasminogen activator inhibitor-1 (PAI-1). Furthermore, a common 4/5 guanosine (4G/5G) polymorphism in the promoter region of the PAI-1 gene has been indicated to influence plasma PAI-1 activity and to be involved in an allele-specific response to triglycerides. Herein we show by transfection assays that VLDLs induce transcription of the human PAI-1 promoter in endothelial cells. A VLDL response element (VLDLRE) is located to residues -672 to -657 in the promoter region by electromobility shift assay, methylation interference, and DNase I footprinting, and its activity is shown to be influenced by the common 4G/5G polymorphism located adjacent to and upstream of the binding site of a VLDL-inducible transcription factor. These findings may provide a molecular explanation to the link between VLDL and PAI-1 activity elevation in plasma and to the interaction between the 4G/5G polymorphism and plasma triglycerides.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Binding, Competitive
  • Cells, Cultured
  • DNA Footprinting
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology*
  • Fibrinolysis / genetics
  • Humans
  • Hypertriglyceridemia / metabolism
  • Lipoproteins, VLDL / pharmacology*
  • Molecular Sequence Data
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Promoter Regions, Genetic / drug effects*
  • Promoter Regions, Genetic / physiology
  • Serine Proteinase Inhibitors / genetics
  • Transcription Factors / metabolism

Substances

  • Lipoproteins, VLDL
  • Plasminogen Activator Inhibitor 1
  • Serine Proteinase Inhibitors
  • Transcription Factors